Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RN7SL325P refers to a specific **pseudogene** classified as "RNA, 7SL, cytoplasmic 325, pseudogene." Pseudogenes are defective copies or nonfunctional segments of genes that have lost their protein-coding ability or function through mutation, truncation, or other genomic rearrangements[1][5][3]. The “7SL RNA” component refers to the functional RNA moiety of the signal recognition particle (SRP), an essential ribonucleoprotein complex involved in targeting secretory proteins to the endoplasmic reticulum during translation[7][8]. However, RN7SL325P is not a functional gene, but an inactive genomic fragment derived from 7SL RNA. It is not known to be transcribed or translated, and is not implicated in any direct biological function or disease pathway[1][5][3]. RN7SL pseudogenes as a whole are highly numerous in the genome due to retrotransposition, but only a handful encode functional 7SL RNA[3][5]. There are no drugs, mechanisms of action, known disease associations, or biomarker roles for RN7SL325P. The inclusion of "pseudogene" and the lack of evidence for activity or biological relevance mean this is **not considered a therapeutic target**; it is essentially a nonfunctional genetic relic[1][5]. **Key notes:** - **This entity is not a receptor, enzyme, transporter, nor does it have a recognized physiological, pathological, or pharmacological role.** - The entry itself is not misspelled but is not a drug-discovery target. “Pseudogene” in the name indicates its nonfunctional nature. - Any references to 7SL RNA’s function are for the canonical, functional gene, not for this pseudogene copy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 325, pseudogene (RN7SL325P).